Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.58 |
| ▸ | FEN1 | P39748 | 1/20 | 0.58 |
| ▸ | CES2 | O00748 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15979733 | 0.82 | CES2 (0.62) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL29987169 | 0.82 | ERCC5 (0.74) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL11264706 | 0.80 | ERCC5 (0.51) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL29560924 | 0.80 | CES2 (0.60) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL1266557 | 0.80 | CES2 (0.60) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL976846 | 0.80 | CES2 (0.60) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL2848421 | 0.80 | CES2 (0.60) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL38141 | 0.78 | ERCC5 (0.58) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL30839506 | 0.78 | ERCC5 (0.58) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL2837238 | 0.78 | ERCC5 (0.58) | ERCC5FEN1CES2CES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107098846-B | N-acyl sulfonamide FBPase inhibitor, preparation method thereof, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-10-09 | — | — | CN | disclosed |
| CN-107098846-A | N- acyl sulfonamides class FBPase inhibitor, its preparation method, pharmaceutical composition and purposes | 中国医学科学院药物研究所 | 2017-08-29 | — | — | CN | disclosed |
| EP-1741693-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS | NAGOYA IND SCIENCE RES INST (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20070225528-A1 | Process for Producing Optically Active Alcohol | NAGOYA INDUSTRIAL SCIENCE RESEARCH CENTER (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1741693-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS | Nagoya Industrial Science Research Institute (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225528-A1 | Process for Producing Optically Active Alcohol | ADH1C, ADH1A, ADH5 | ERCC5 4420/4885FEN1 4394/4885CES2 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.